1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Ischemic Stroke in 2 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Ischemic Stroke: Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Additionally, our previous studies reported that combination therapy with liposomal fasudil plus tissue plasminogen activator (t-PA), a thrombolytic agent, brings about decrease in the risk of t-PA-derived cerebral hemorrhage and prolong the therapeutic time window of t-PA for treating acute ischemic stroke." | 5.12 | [Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke]. ( Fukuta, T, 2021) |
| "Our findings suggest that fasudil is a BBB-protective agent against acute ischemic stroke." | 4.12 | Effects of fasudil on blood-brain barrier integrity. ( Deli, MA; Fujimoto, T; Izumo, T; Matsunaga, Y; Matsuo, T; Morofuji, Y; Nakagawa, S; Niwa, M; Santa-Maria, AR; Sato, K; Vigh, JP; Walter, FR; Watanabe, D, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuta, T | 1 |
| Sato, K | 1 |
| Nakagawa, S | 1 |
| Morofuji, Y | 1 |
| Matsunaga, Y | 1 |
| Fujimoto, T | 1 |
| Watanabe, D | 1 |
| Izumo, T | 1 |
| Niwa, M | 1 |
| Walter, FR | 1 |
| Vigh, JP | 1 |
| Santa-Maria, AR | 1 |
| Deli, MA | 1 |
| Matsuo, T | 1 |
1 review available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Ischemic Stroke
| Article | Year |
|---|---|
[Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood-Brain Barrier; Capillary Permeability; | 2021 |
1 other study available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Ischemic Stroke
| Article | Year |
|---|---|
Effects of fasudil on blood-brain barrier integrity.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13 | 2022 |